Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Sep 10 - Sep 15
Lilly is building a multi-engine growth machine: Alzheimer's Treatment Kisunla (Donanemab) - FDA-approved for early Alzheimer's, first proven to slow cognitive decline Represents a breakthrough in neurodegenerative disease treatment Oncology & Immunology Verzenio (breast cancer): $1.47B in Q3 2025 (+7% YoY) Jaypirca and Omvoh expanding in oncology and autoimmune markets Radiopharmaceutical investments through Point Biopharma ($1.4B acquisition) and Aktis Oncology partnership Pipeline Depth 40+ programs in Phase 2/3 across neuroscience, immunology, and cardiology Recent acquisitions: Scorpion Therapeutics, SiteOne Therapeutics, Adverum Biotechnologies Lilly isn't a one-trick pony
Reasons for GLP-1 discontinuation (e.g., cost, side effects, clinical decision) were not available
In a landmark trial published in The New England Journal of Medicine, semaglutide significantly improved metabolic markers alongside weight reduction
Ozempic, whose active ingredient is semaglutide, is designed to mimic the beneficial actions of natural GLP-1
Willow is not actually the cheapest option for compounded GLP-1 medications
That is not a win
US$ 27.63
US$ 26.85
US$ 23.65
